1. NAACCR/IACR Combined Annual Conference 6/11/2019, Vancouver, Canada
Primary Malignant Cardiac Tumors in California Lihua Liu, PhD Los Angeles Cancer Surveillance Program University of Southern California
NAACCR/IACR Combined Annual Conference
6/11/2019, Vancouver, Canada

2. Primary Malignant Cardiac Tumor (PMCT)
Cancer occurring in the heart
Rare (AAIR=0.034/100,0001)
Highly fatal (Median survival=10 months1)
Most are diagnosed at late stage
Under-researched
Poorly understood
1. Oliveira GH, Al-Kindi SG, Christopher DOH, Park SJ. Characteristics and Survival of Malignant Cardiac Tumors A 40-Year Analysis of >500 Patients. Circulation, December 2015:

3. Methods California Cancer Registry (CCR) data (1988-2016)
SEER site recode (soft tissue incl. heart) & ICD-O-3 (heart)
N = 247
PMCT disparities by patient and tumor characteristics
Case distributions
Incidence rates (age-adjusted, age-specific)
Survival (Kaplan–Meier estimates, Cox regression analysis)

4. PMCT Case Distribution by Race/ethnicity, California, 1988-2016 (N=247)

5. PMCT Age-Adjusted Incidence Rates (AAIR) by Race/ethnicity California, 1988-2016

6. PMCT Case Distribution by Age Group, California, 1988-2016 (N=247)

7. PMCT Age-Specific Incidence Rates (ASIR) by Race/ethnicity California, 1988-2016

8. Trends of PMCT AAIR by Sex, California, 1988-2016

9. PMCT Case Distribution by Tumor Stage at Diagnosis, California, 1988-2016 (N=247)

10. PMCT Observed Survival by Tumor Stage, California, 1988-2016

11. PMCT Case Distribution by Treatment Type, California, 1988-2016 (N=247)

12. PMCT Observed Survival by Treatment Type, California, 1988-2016

13. Multivariate analysis –
Hazard Ratios

14. Summary
PMCT incidence rates are similar between males and females, but higher in NH blacks and Hispanics (not statistically significant, maybe due to small numbers)
Risk of PMCT increases with age, AAIR trends rising slightly
Only 27% of PMCT patients were diagnosed at localized stage
Observed 3-year survival is below 20%
Early stage diagnosis and combination of treatment modalities lead to the best outcomes
Mining cancer registry data can provide valuable information for understanding PMCT and improving diagnosis and survival

15. Acknowledgments University of Southern California
Megan Loo, MD, MPH, Cardiothoracic Surgery Resident
Juanjuan Zhang, MS, Dept. of Preventive Medicine
Sue E. Kim, PhD, Dept. of Preventive Medicine
Michael Bowdish, MD, MS, Depts. of Surgery and Preventive Medicine
The collection of cancer incidence data used in this study was supported by the California Department of Public Health pursuant to California Health and Safety Code Section ; Centers for Disease Control and Prevention’s (CDC) National Program of Cancer Registries, under cooperative agreement 5NU58DP006344; the National Cancer Institute’s Surveillance, Epidemiology and End Results Program under contract HHSN I awarded to the University of California, San Francisco, contract HHSN I awarded to the University of Southern California, and contract HHSN I awarded to the Public Health Institute. The ideas and opinions expressed herein are those of the author(s) and do not necessarily reflect the opinions of the State of California, Department of Public Health, the National Cancer Institute, and the Centers for Disease Control and Prevention or their Contractors and Subcontractors.